Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Abstract Text:

Holly Heaslet,Ying-Chuan Lin,Karen Tam,Bruce E Torbett,John H Elder,C David Stout,

We have obtained the 1.7 A crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of HIV PR (12X FIV PR). The chimeric PR was crystallized in complex with the broad-based inhibitor TL-3, which inhibits wild type FIV and HIV PRs, as well as 12X FIV PR and several drug-resistant HIV mutants 1234. Biochemical analyses have demonstrated that TL-3 inhibits these PRs in the order HIV PR > 12X FIV PR > FIV PR, with Ki values of 1.5 nM, 10 nM, and 41 nM, respectively 234. Comparison of the crystal structures of the TL-3 complexes of 12X FIV and wild-typeFIV PR revealed theformation of additinal van der Waals interactions between the enzyme inhibitor in the mutant PR. The 12X FIV PR retained the hydrogen bonding interactions between residues in the flap regions and active site involving the enzyme and the TL-3 inhibitor in comparison to both FIV PR and HIV PR. However, the flap regions of the 12X FIV PR more closely resemble those of HIV PR, having gained several stabilizing intra-flap interactions not present in wild type FIV PR. These findings offer a structural explanation for the observed inhibitor/substrate binding properties of the chimeric PR.

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Publishing Authors By Initials

H Heaslet,YC Lin,K Tam,BE Torbett,JH Elder,CD Stout,

For similar proteins: recombinant proteins: recombinant fusion proteins research abstracts see: proteins: recombinant proteins: recombinant fusion proteins research

PUBMED ID PMID:

MEDLINE DATE:

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Retrovirology

VOLUME: 4

Page Numbers: 1

Journal Abbreviation: Retrovirology

ISSN: 1742-4690

DAY: 9

MONTH: 01

YEAR: 2007

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101216893

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Keywords Mesh Terms:

KEYWORDS: Recombinant Fusion Proteins

MESH TERMS: chemistry

Chemical & Substance for Abstract: Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Information

Substance Name: HIV Protease

Registry Number: EC 3.4.23.-

Grant and Affiliation Information for Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.

AFFILIATION: Pfizer Global Research & Development, 2800 Plymouth Rd., Ann Arbor, MI 48105, USA. hheaslet@scripps.edu

Country: England

AGENCY: United States NIGMS

GRANT: GM48870

ACRONYM: GM

MEDLINETA: Retrovirology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3 Related Publications

• Absorption and scattering properties of dense ensembles of nonspherical particles.
• Acute effects of static versus dynamic stretching on isometric strength and neuromuscular function of the leg flexors: 2356: board #35 june 1 3:30 PM -5:00 PM.
• Advancing the analysis of treatment process.
• An examination of main and interactive effects of substance abuse recovery housing on multiple indicators of adjustment.
• Conformational flexibility in the flap domains of ligand-free HIV protease.
• Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.
• Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs.
• Fibrosarcoma of cicatrix of thoracic wall.
• Granuloma of the lung.
• IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.
• Identification of novel alternatively spliced isoforms of RTEF-1 within human ocular vascular endothelial cells and murine retina.
• Lesions of the breast.
• Lymphosarcoma, lymphocytic cell type, of the temporal region.
• Malignant melanoma of the anal canal.
• Multiple squamous cell epitheliomas of the scalp arising from hair follicles? or sebaceous cysts?
• Myxoma of zygomatic bone.
• Natural course of bulimia nervosa and of eating disorder not otherwise specified: 5-year prospective study of remissions, relapses, and the effects of personality disorder psychopathology.
• Papillary carcinoma of nasal cavity.
• Papillary carcinoma of the thyroid.
• Papillary squamous cell epithelioma of gum of mandible.
• Plasmocytoma of inframammary region.
• Primary care. PCTs under pressure to open doors wider.
• Time course for the acute effects of passive stretching on isometric strength and neuromuscular function: 2361: board #40 june 1 3:30 PM -5:00 PM.
• Tumors of the peripheral nervous system.
• Validity of BIA for Estimating Body Fat in Healthy Males and Females: 2101: Board #14 June 1 8:00 AM - 9:30 AM.
• Validity of Laboratory and Field Methods for Estimating Percent Fat in College Aged Caucasian Women: 2104: Board #17 June 1 8:00 AM - 9:30 AM.
• Validity of Laboratory and Field Methods for Estimating Percent Fat in College-Age Males: 2098: Board #11 June 1 8:00 AM - 9:30 AM.
• Validity of New Near Infrared Interactance Device (NIR) for Estimating Percent Fat in College-aged Men and Women: 2100: Board #13 June 1 8:00 AM - 9:30 AM.
• [Commentary] REGRESSION TO THE MEAN IN ADDICTION RESEARCH.
• [Not Available.]